Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Current Assets:
Cash and cash equivalents	$ 70,072,946	$ 13,859,748
Prepaid expenses	2,741,404	122,237
Total Current Assets	72,814,350	13,981,985
Property and equipment, net	7,023	1,577
Operating lease right-of-use asset, net	822,828	986,204
Other Assets:
Deposits	38,062	57,093
In-process research and development	59,400,000	19,400,000
Goodwill	9,346,796	9,346,796
Total Other Assets	68,784,858	28,803,889
Total Assets	142,429,059	43,773,655
Current Liabilities:
Accounts payable	1,277,095	1,856,235
Accrued expenses	621,960	164,040
Accrued compensation	1,906,000	1,654,919
Accrued interest		89,970
Notes payable – related parties		172,970
Operating lease liability	177,237	158,999
Total Current Liabilities	3,982,292	4,097,133
Note payable – paycheck protection program		164,583
Deferred tax liability	4,985,800	4,985,800
Operating lease liability – non current	678,234	855,471
Total Liabilities	9,646,326	10,102,987
Commitments and Contingencies
Stockholders’ Equity:
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - $0.001 par value; 400,000,000 shares authorized; 145,979,429 and 55,576,996 shares issued and outstanding at September 30, 2021 and 2020, respectively	145,979	55,577
Additional paid-in capital	228,084,195	104,208,958
Accumulated deficit	(96,047,821)	(70,593,867)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity	132,182,353	33,670,668
Non-controlling interest	600,380
Total Equity	132,782,733	33,670,668
Total Liabilities and Equity	$ 142,429,059	$ 43,773,655

Amount of in process research and development.

No definition available.

Name:	ctxr_InProcessResearchAndDevelopment
Namespace Prefix:	ctxr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).